Oyinkan Sofola-Adesakin

Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer’s disease

Fiona Kerr, Oyinkan Sofola-Adesakin, Dobril Ivanov et al. · PLoS Genetics · 2017 · 142 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17

Lithium suppresses Aβ pathology by inhibiting translation in an adult Drosophila model of Alzheimer's disease

Oyinkan Sofola-Adesakin, Jorge Iván Castillo-Quan, Charalampos Rallis et al. · Frontiers in Aging Neuroscience · 2014 · 104 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Molecular Mechanisms of Lithium Action: Switching the Light on Multiple Targets for Dementia Using Animal Models

Fiona Kerr, Ivana Bjedov, Oyinkan Sofola-Adesakin · Frontiers in Molecular Neuroscience · 2018 · 79 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17

pGluAβ increases accumulation of Aβ in vivo and exacerbates its toxicity

Oyinkan Sofola-Adesakin, Mobina Khericha, Inge Snoeren et al. · Acta Neuropathologica Communications · 2016 · 35 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity

Marianna Karina Gorsky, Sylvie Burnouf, Oyinkan Sofola-Adesakin et al. · Scientific Reports · 2017 · 35 citations · Full text

Life Sciences, Molecular Biology, Neuroscience +17